Sarcoplasmic MxA expression A valuable marker of dermatomyositis

Akinori Uruha, Atsuko Nishikawa, Rie S. Tsuburaya, Kohei Hamanaka, Masataka Kuwana, Yurika Watanabe, Shigeaki Suzuki, Norihiro Suzuki, Ichizo Nishino

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Objective: To evaluate the diagnostic value of myxovirus resistance A (MxA) expression in the cytoplasm of myofibers in the diagnosis of dermatomyositis (DM). Methods: We assessed the sensitivity and specificity of the sarcoplasmic expression of MxA in muscles with DM by immunohistochemistry in consecutive cases of DM (n 5 34) and other idiopathic inflammatory myopathies (n 5120: 8 with polymyositis, 16 with anti-TRNA-synthetase antibody-Associated myositis, 46 with immune-mediated necrotizing myopathy, and 50 with inclusion body myositis) and compared them with conventional pathologic hallmarks of DM, including perifascicular atrophy (PFA) and membrane attack complex (MAC) deposition on endomysial capillaries. Results: The sensitivity and specificity of sarcoplasmic MxA expression were 71% and 98%, respectively. While the specificity was almost comparable to that of PFA and capillary MAC deposition, the sensitivity was higher, with PFA showing 47% sensitivity and 98% specificity and capillary MAC deposition showing 35% sensitivity and 93% specificity. Of note, in patients with DM with typical skin rash but no PFA, 44% of the samples showed sarcoplasmic MxA expression, which was higher than the 17% sensitivity of capillary MAC deposition in the population. Conclusions: Sarcoplasmic MxA expression detected by immunohistochemistry is a more sensitive marker of DM than the conventional hallmarks, indicating its practical utility in the diagnosis of DM. It may well be included in the routine immunohistochemistry panel for myositis.

Original languageEnglish
Pages (from-to)493-500
Number of pages8
JournalNeurology
Volume88
Issue number5
DOIs
Publication statusPublished - 2017 Jan 31
Externally publishedYes

Fingerprint

Dermatomyositis
Orthomyxoviridae
Complement Membrane Attack Complex
Myositis
Atrophy
Sensitivity and Specificity
Immunohistochemistry
Inclusion Body Myositis
Polymyositis
Muscular Diseases
Ligases
Exanthema
Cytoplasm
Muscles
Antibodies
Population

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Uruha, A., Nishikawa, A., Tsuburaya, R. S., Hamanaka, K., Kuwana, M., Watanabe, Y., ... Nishino, I. (2017). Sarcoplasmic MxA expression A valuable marker of dermatomyositis. Neurology, 88(5), 493-500. https://doi.org/10.1212/WNL.0000000000003568

Sarcoplasmic MxA expression A valuable marker of dermatomyositis. / Uruha, Akinori; Nishikawa, Atsuko; Tsuburaya, Rie S.; Hamanaka, Kohei; Kuwana, Masataka; Watanabe, Yurika; Suzuki, Shigeaki; Suzuki, Norihiro; Nishino, Ichizo.

In: Neurology, Vol. 88, No. 5, 31.01.2017, p. 493-500.

Research output: Contribution to journalArticle

Uruha, A, Nishikawa, A, Tsuburaya, RS, Hamanaka, K, Kuwana, M, Watanabe, Y, Suzuki, S, Suzuki, N & Nishino, I 2017, 'Sarcoplasmic MxA expression A valuable marker of dermatomyositis', Neurology, vol. 88, no. 5, pp. 493-500. https://doi.org/10.1212/WNL.0000000000003568
Uruha A, Nishikawa A, Tsuburaya RS, Hamanaka K, Kuwana M, Watanabe Y et al. Sarcoplasmic MxA expression A valuable marker of dermatomyositis. Neurology. 2017 Jan 31;88(5):493-500. https://doi.org/10.1212/WNL.0000000000003568
Uruha, Akinori ; Nishikawa, Atsuko ; Tsuburaya, Rie S. ; Hamanaka, Kohei ; Kuwana, Masataka ; Watanabe, Yurika ; Suzuki, Shigeaki ; Suzuki, Norihiro ; Nishino, Ichizo. / Sarcoplasmic MxA expression A valuable marker of dermatomyositis. In: Neurology. 2017 ; Vol. 88, No. 5. pp. 493-500.
@article{0f69cad966d943408fdf15a7170a724b,
title = "Sarcoplasmic MxA expression A valuable marker of dermatomyositis",
abstract = "Objective: To evaluate the diagnostic value of myxovirus resistance A (MxA) expression in the cytoplasm of myofibers in the diagnosis of dermatomyositis (DM). Methods: We assessed the sensitivity and specificity of the sarcoplasmic expression of MxA in muscles with DM by immunohistochemistry in consecutive cases of DM (n 5 34) and other idiopathic inflammatory myopathies (n 5120: 8 with polymyositis, 16 with anti-TRNA-synthetase antibody-Associated myositis, 46 with immune-mediated necrotizing myopathy, and 50 with inclusion body myositis) and compared them with conventional pathologic hallmarks of DM, including perifascicular atrophy (PFA) and membrane attack complex (MAC) deposition on endomysial capillaries. Results: The sensitivity and specificity of sarcoplasmic MxA expression were 71{\%} and 98{\%}, respectively. While the specificity was almost comparable to that of PFA and capillary MAC deposition, the sensitivity was higher, with PFA showing 47{\%} sensitivity and 98{\%} specificity and capillary MAC deposition showing 35{\%} sensitivity and 93{\%} specificity. Of note, in patients with DM with typical skin rash but no PFA, 44{\%} of the samples showed sarcoplasmic MxA expression, which was higher than the 17{\%} sensitivity of capillary MAC deposition in the population. Conclusions: Sarcoplasmic MxA expression detected by immunohistochemistry is a more sensitive marker of DM than the conventional hallmarks, indicating its practical utility in the diagnosis of DM. It may well be included in the routine immunohistochemistry panel for myositis.",
author = "Akinori Uruha and Atsuko Nishikawa and Tsuburaya, {Rie S.} and Kohei Hamanaka and Masataka Kuwana and Yurika Watanabe and Shigeaki Suzuki and Norihiro Suzuki and Ichizo Nishino",
year = "2017",
month = "1",
day = "31",
doi = "10.1212/WNL.0000000000003568",
language = "English",
volume = "88",
pages = "493--500",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Sarcoplasmic MxA expression A valuable marker of dermatomyositis

AU - Uruha, Akinori

AU - Nishikawa, Atsuko

AU - Tsuburaya, Rie S.

AU - Hamanaka, Kohei

AU - Kuwana, Masataka

AU - Watanabe, Yurika

AU - Suzuki, Shigeaki

AU - Suzuki, Norihiro

AU - Nishino, Ichizo

PY - 2017/1/31

Y1 - 2017/1/31

N2 - Objective: To evaluate the diagnostic value of myxovirus resistance A (MxA) expression in the cytoplasm of myofibers in the diagnosis of dermatomyositis (DM). Methods: We assessed the sensitivity and specificity of the sarcoplasmic expression of MxA in muscles with DM by immunohistochemistry in consecutive cases of DM (n 5 34) and other idiopathic inflammatory myopathies (n 5120: 8 with polymyositis, 16 with anti-TRNA-synthetase antibody-Associated myositis, 46 with immune-mediated necrotizing myopathy, and 50 with inclusion body myositis) and compared them with conventional pathologic hallmarks of DM, including perifascicular atrophy (PFA) and membrane attack complex (MAC) deposition on endomysial capillaries. Results: The sensitivity and specificity of sarcoplasmic MxA expression were 71% and 98%, respectively. While the specificity was almost comparable to that of PFA and capillary MAC deposition, the sensitivity was higher, with PFA showing 47% sensitivity and 98% specificity and capillary MAC deposition showing 35% sensitivity and 93% specificity. Of note, in patients with DM with typical skin rash but no PFA, 44% of the samples showed sarcoplasmic MxA expression, which was higher than the 17% sensitivity of capillary MAC deposition in the population. Conclusions: Sarcoplasmic MxA expression detected by immunohistochemistry is a more sensitive marker of DM than the conventional hallmarks, indicating its practical utility in the diagnosis of DM. It may well be included in the routine immunohistochemistry panel for myositis.

AB - Objective: To evaluate the diagnostic value of myxovirus resistance A (MxA) expression in the cytoplasm of myofibers in the diagnosis of dermatomyositis (DM). Methods: We assessed the sensitivity and specificity of the sarcoplasmic expression of MxA in muscles with DM by immunohistochemistry in consecutive cases of DM (n 5 34) and other idiopathic inflammatory myopathies (n 5120: 8 with polymyositis, 16 with anti-TRNA-synthetase antibody-Associated myositis, 46 with immune-mediated necrotizing myopathy, and 50 with inclusion body myositis) and compared them with conventional pathologic hallmarks of DM, including perifascicular atrophy (PFA) and membrane attack complex (MAC) deposition on endomysial capillaries. Results: The sensitivity and specificity of sarcoplasmic MxA expression were 71% and 98%, respectively. While the specificity was almost comparable to that of PFA and capillary MAC deposition, the sensitivity was higher, with PFA showing 47% sensitivity and 98% specificity and capillary MAC deposition showing 35% sensitivity and 93% specificity. Of note, in patients with DM with typical skin rash but no PFA, 44% of the samples showed sarcoplasmic MxA expression, which was higher than the 17% sensitivity of capillary MAC deposition in the population. Conclusions: Sarcoplasmic MxA expression detected by immunohistochemistry is a more sensitive marker of DM than the conventional hallmarks, indicating its practical utility in the diagnosis of DM. It may well be included in the routine immunohistochemistry panel for myositis.

UR - http://www.scopus.com/inward/record.url?scp=85011275788&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011275788&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000003568

DO - 10.1212/WNL.0000000000003568

M3 - Article

VL - 88

SP - 493

EP - 500

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 5

ER -